OPR - Delayed Quote • USD TARA Aug 2024 7.500 call (TARA240816C00007500) Follow 0.3000 0.0000 (0.00%) At close: April 22 at 10:10 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for TARA240816C00007500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: TARA Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate Protara Therapeutics to Participate in Upcoming Investor Conferences Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
